Henlez mission is to transform the management of skin conditions by using enzymes.
Henlez’s pre-clinical lead development program, HEN-001, is an enzyme-based, topical application directed towards hidradenitis suppurativa (HS) – a highly stigmatizing and chronic inflammatory condition characterized by severe pain, malodorous drainage and permanent scarring of the armpits and groin. The company was founded 2019 by former Novozymes A/S scientist and current CEO Jeppe Mouritsen.
http://henlez.com/
Location: Denmark, Capital Region of Denmark, Copenhagen
Employees: 1-10
Total raised: $1M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Eir Ventur... | eirventure... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.10.2022 | Seed | $1M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 09.09.2023 | Bio-Innovation Blooms: 15 Cutting-Edge Biotechnology Startup... | Denmark, known for its picturesque landscapes and rich culture, is also a fertile ground for biotech... | eustartup.... |
| 27.10.2022 | Henlez Raises €1M in Seed Funding | Henlez, a Danish startup advancing treatments for chronic dermatological condition hidradenitis supp... | finsmes.co... |
| - | Henlez | “Henlez is a Danish startup company.” | fastfounde... |